Allegra Formulation

Allegra is an antihistamine used to treat the symptoms of allergic rhinitis i.e. allergies and seasonal hay fever. Allegra is to be taken orally, with or without food. Do not crush or chew extended-release tablets. Allegra is available in various strengths by different names, namely:

• Allegra
• Allegra-D 24 Hour
• Allegra-D 12 Hour
• Allegra 60 mg.
• Allegra 30 mg.

Allegra
One dose of long lasting Allegra 180 mg relieves your seasonal allergy symptoms, like sneezing, itchy, watery, red eyes and runny nose, up-to 4 times longer than one dose of many other allergy medicines.

Allegra-D 24 Hour
Allegra-D 24 Hour comes as an advanced form of the Allegra 180 mg. It's a powerful decongestant, that solves the common allergy problem i.e. congestion along with being non-drowsy. One dose of the medicine last much longer as compared to the other medicines that are normally available.

Allegra-D 12 Hour
Allegra D 12 Hour is an antihistamine. This drug gives the freedom to both the doctor and patient to build a flexible treatment plan that suits to the individual time-table or their requirements.

Allegra 60 mg
Allegra 60 mg provides relief to patients from twelve years and above from the seasonal allergy symptoms like the running nose, itchy nose or throat, sneezing and even to the itchy/red or watery eyes.

Allegra 30 mg
Allegra 30 mg provides relief to children from six to eleven years of age .The duration of this relief from sneezing, running nose, itching nose or throat, itchy or watery red eyes lasts for twelve hours.

DRUG MANUFACTURING COMPANY

Sanofi-Aventis
Sanofi-aventis is the world's 3rd largest pharmaceutical company, ranking number 1 in Europe and ranks among the top 5 in the United States. Sanofi-aventis conducts business in the U.S. through its headquarters in Bridgewater, New Jersey. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Corporate headquarters are in Paris, France, backed up by a world-class R&D organization

Sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines. In 2005, Sanofi-aventis generated sales of approximately € 27.3 billion, invested more than € 4.00 billion (among the top 3 globally) in research and development, and employed approximately 100,000 people in its core business.

Aventis Pharmaceuticals
The U.S. pharmaceutical company of Aventis S.A is one of the world's leading life sciences companies. The corporate headquarters of Aventis Pharma is in Frankfurt, Germany. The company's North America Commercial headquarters is in Parsippany, N.J. is closely aligned with Aventis Pharma are Aventis Pasteur, a world leader in vaccines based in Lyon, France, and Aventis Behring, a world leader in therapeutic vaccines with corporate headquarters in King of Prussia, Pennsylvania, USA.

Aventis Pharmaceuticals focuses its activities on important therapeutic areas. On a global basis, Aventis Pharma AG is dedicated to treating and preventing human disease through the discovery, development, manufacture and sale of innovative pharmaceutical products aimed at fulfilling unmet medical needs. Aventis Pharmaceuticals focuses its activities on important therapeutic areas.